Welcome to our dedicated page for NovaBay Pharmaceuticals news (Ticker: NBY), a resource for investors and traders seeking the latest updates and insights on NovaBay Pharmaceuticals stock.
NovaBay Pharmaceuticals, Inc. (symbol: NBY) is a pioneering biopharmaceutical company dedicated to the development, commercialization, and sale of non-antibiotic anti-infective products. The company's core focus lies in addressing the unmet therapeutic needs of the global eye care market. NovaBay has successfully introduced two distinct product categories: the Neutrox™ family of products and Aganocide® compounds.
The Neutrox™ family is spearheaded by Avenova™, a prescription lid and lash hygiene product designed for managing chronic eye conditions such as blepharitis and meibomian gland dysfunction, commonly known as dry eye syndrome. Affecting an estimated 30 million Americans, these conditions represent a substantial annual market potential, which NovaBay estimates to be around $500 million. Avenova is available for order in 90% of all pharmacies across the United States and is gaining market traction through its 35 medical direct sales representatives under veteran leadership.
Additionally, the Neutrox™ family includes NeutroPhase® for wound care and CellarX™ for dermatology applications. The Aganocide® compounds are led by Auriclosene™, further showcasing NovaBay's innovative approach to non-antibiotic therapies.
NovaBay's flagship product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to possess broad antimicrobial properties. It effectively removes foreign material, including microorganisms and debris from the skin around the eye, making it a valuable tool for eyecare professionals to manage blepharitis and dry-eye disease. Avenova Spray is available to consumers both through online distribution channels and as a prescription product dispensed by eyecare professionals.
NovaBay Pharmaceuticals operates two main segments: Eyecare, and Wound Care and Skincare. This diversified approach allows the company to leverage its expertise in antimicrobial solutions across multiple therapeutic areas, thereby expanding its market reach and impact.
Financially, NovaBay continues to strengthen its market position through strategic partnerships and continuous innovation. The company's relentless pursuit of excellence in eyecare and skincare underscores its commitment to improving patient outcomes globally.
NovaBay Pharmaceuticals (NYSE American: NBY) reported record sales of Avenova eyecare products during Amazon Prime Day 2024. Sales were 17% higher compared to Prime Day 2023 and 40% up from Prime Day 2022. CEO Justin Hall attributed the success to discounts on high-quality Avenova products, attracting both repeat and new customers.
NovaBay offers a full portfolio of dry eye products, including Avenova Lid & Lash Solution, Lubricating Eye Drops, Warm Eye Compress, and i-Chek for eyelid health monitoring. The company aims to become a one-stop destination for the 25 million Americans suffering from dry eye disease, addressing the rising prevalence and multifactorial nature of the condition.
NovaBay Pharmaceuticals (NYSE American: NBY) has closed its previously announced underwritten public offering, raising approximately $3.87 million in gross proceeds. The offering included common stock, pre-funded warrants, and three series of warrants (F-1, F-2, and F-3). The combined public offering price was $1.10 per share of common stock and accompanying warrants, and $1.09 for each pre-funded warrant and accompanying warrants. Ladenburg Thalmann & Co. Inc. acted as the sole bookrunning manager. NovaBay intends to use the net proceeds to redeem outstanding convertible debentures and for working capital and general corporate purposes.
NovaBay Pharmaceuticals (NYSE American: NBY) has announced the pricing of a $3.5 million underwritten public offering. The offering includes 3,200,380 shares of common stock (or pre-funded warrants) and three series of warrants (F-1, F-2, and F-3) at a combined public offering price of $1.10 per share. Each warrant series allows the purchase of up to 3,200,380 additional shares. Ladenburg Thalmann & Co. Inc. is acting as the sole bookrunning manager. The company plans to use the proceeds to redeem outstanding convertible debentures and for working capital. The offering is expected to close around July 29, 2024, subject to customary conditions.
NovaBay Pharmaceuticals (NYSE American: NBY) is offering 20% discounts on Avenova eyecare products and bundles during Amazon Prime Day on July 16-17, 2024. This event coincides with National Dry Eye Awareness Month, targeting a condition affecting 25 million Americans. CEO Justin Hall notes that Prime Day has been highly productive for NovaBay in the past, allowing loyal customers to stock up and new users to try their products.
The company's Avenova Subscribe & Save customers on Amazon, their largest sales channel, have increased by 123% since early 2022. NovaBay offers a full portfolio of scientifically developed products for at-home dry eye treatment, including Lid & Lash Solution, Lubricating Eye Drops, Warm Eye Compress, and the i-Chek monitor.
NovaBay Pharmaceuticals (NYSE American: NBY) reported preliminary net revenue of $2.4 million for Q2 2024 and $5.0 million for H1 2024, mainly from eyecare products. Eyecare revenue grew 9% over the same periods in 2023, driven by higher online sales. The number of Avenova subscribers on Amazon surged 64% since early 2023 and 123% since 2022. NovaBay anticipates 2024 eyecare revenue of around $10 million. CEO Justin Hall highlighted the importance of loyal Amazon and Avenova.com subscribers, who accounted for 23% of online Avenova sales in H1 2024. The subscriber base increased by 16% in the first half of 2024. NovaBay's digital marketing strategies have been cost-efficient, leading to projected lower sales and marketing expenses despite revenue growth.
NovaBay Pharmaceuticals and Eyenovia have started joint promotional activities to market NovaBay's Avenova® Antimicrobial Lid & Lash Solution and Eyenovia's MydCombi™ for mydriasis to large ophthalmic surgery centers. Eyenovia's salesforce will promote Avenova, while NovaBay prepares for Eyenovia's upcoming launch of Clobetasol Propionate Ophthalmic Suspension, 0.05% in August 2024. This partnership aims to enhance market presence and awareness for both companies' products, leveraging NovaBay's established network of eyecare professionals. Prescription Avenova is available through EyenoviaRx.com and Avenova.com, with the non-prescription version on Amazon.com.
NovaBay Pharmaceuticals announces special promotions on Avenova eyecare products for National Dry Eye Awareness Month in July. The company aims to educate the public about dry eye disease, which affects 25 million people in the U.S. Customers can avail a 15% discount and free shipping on Avenova products through Amazon.com and Avenova.com. Special offers are also available for eyecare professionals, particularly those using intense pulsed light (IPL) and thermal pulsation treatments. Avenova's range includes sprays, eye drops, warm compresses, dietary supplements, and health monitors, all designed to provide relief from dry eye symptoms.
NovaBay Pharmaceuticals (NBY) announced that the NYSE American has accepted its compliance plan, allowing the company to remain listed while working towards meeting NYSE listing standards. Following the divestiture of an unprofitable segment, NovaBay is now focusing on its core eyecare business, particularly its Avenova®-branded products. The NYSE American has reviewed the plan and acknowledged NovaBay's potential to regain compliance by October 18, 2025, with quarterly reviews until then. Failure to meet these standards could result in delisting proceedings. The company had previously been notified on April 18 and May 28, 2024, about non-compliance due to inadequate stockholders' equity, but this does not affect its business operations or SEC reporting requirements.
NovaBay Pharmaceuticals announced the approval of all proposals at its 2024 Annual Meeting, including a 1-for-35 reverse stock split. This decision aims to align with the NYSE American's listing standards and enhance stock marketability and liquidity. The reverse stock split will be effective on May 30, 2024, and shares will trade on a split-adjusted basis from May 31, 2024.
Additionally, NovaBay received a notice from NYSE American regarding non-compliance with stockholders’ equity requirements. They have until October 18, 2025, to meet these standards or face potential delisting. The company's recent financial statements included a going concern notice, highlighting ongoing financial challenges.
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) introduces an expanded line of Avenova product bundles to address individualized relief from dry eye symptoms. The U.S. market for dry eye treatment is projected to reach $4.86 billion by 2030, with approximately 16 million Americans suffering from dry eye disease. The new Avenova bundles align with optometrists' recommendations for personalized treatment beyond artificial tears, offering easy, affordable, and effective solutions for managing dry eye symptoms.
FAQ
What is the current stock price of NovaBay Pharmaceuticals (NBY)?
What is the market cap of NovaBay Pharmaceuticals (NBY)?
What does NovaBay Pharmaceuticals do?
What is Avenova?
Where can I buy Avenova?
What are the main segments in which NovaBay operates?
What is the market potential for Avenova?
What are NeutroPhase and CellarX?
What are Aganocide compounds?
How is Avenova beneficial for eye care?
Who leads the sales efforts for Avenova?